Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Anterior urethra sparing cystoprostatectomy for bladder cancer: a 10-year, single center experience.

Hayakawa N, Kikuno N, Ishihara H, Ryoji O, Tanabe K.

Springerplus. 2015 Aug 8;4:401. doi: 10.1186/s40064-015-1200-7. eCollection 2015.

2.

Retroperitoneal catecholamine-producing ganglioneuroma with a birth history of monozygotic twins who both suffered from neuroblastoma during their childhoods: a case report with genome analysis.

Ishihara H, Kikuno N, Hayakawa N, Ryoji O, Tanabe K.

J Neurol Sci. 2015 Oct 15;357(1-2):329-31. doi: 10.1016/j.jns.2015.07.041. Epub 2015 Jul 30. No abstract available.

PMID:
26248704
3.

Brain metastasis in a patient with a sarcomatoid variant RCC with well-controlled extracerebral metastases by temsirolimus.

Kikuno N, Kennoki T, Fukuda H, Matsumoto Y, Tsunoyama K, Ban S, Satoh H, Ryoji O.

Anticancer Res. 2012 Aug;32(8):3443-7.

PMID:
22843928
4.

Case of IgG4-related retroperitoneal fibrosis with concomitant rheumatoid arthritis.

Kikuno N, Sato H, Ryoji O.

Int J Urol. 2010 Dec;17(12):1011-2. doi: 10.1111/j.1442-2042.2010.02660.x. No abstract available.

5.

Wnt antagonist DKK1 acts as a tumor suppressor gene that induces apoptosis and inhibits proliferation in human renal cell carcinoma.

Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Ueno K, Yamamura S, Zaman MS, Khatri G, Chen Y, Saini S, Majid S, Deng G, Ishii N, Dahiya R.

Int J Cancer. 2011 Apr 15;128(8):1793-803. doi: 10.1002/ijc.25507.

6.

Functional significance of Wnt inhibitory factor-1 gene in kidney cancer.

Kawakami K, Hirata H, Yamamura S, Kikuno N, Saini S, Majid S, Tanaka Y, Kawamoto K, Enokida H, Nakagawa M, Dahiya R.

Cancer Res. 2009 Nov 15;69(22):8603-10. doi: 10.1158/0008-5472.CAN-09-2534. Epub 2009 Nov 3.

7.

Restoring erectile function by antioxidant therapy in diabetic rats.

Hirata H, Kawamoto K, Kikuno N, Kawakami T, Kawakami K, Saini S, Yamamura S, Dahiya R.

J Urol. 2009 Nov;182(5):2518-25. doi: 10.1016/j.juro.2009.07.009. Epub 2009 Sep 17.

PMID:
19765757
8.

Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways.

Hirata H, Hinoda Y, Nakajima K, Kawamoto K, Kikuno N, Kawakami K, Yamamura S, Ueno K, Majid S, Saini S, Ishii N, Dahiya R.

Clin Cancer Res. 2009 Sep 15;15(18):5678-87. doi: 10.1158/1078-0432.CCR-09-0558.

9.

Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials.

Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK.

Ann Oncol. 2010 Feb;21(2):312-8. doi: 10.1093/annonc/mdp308. Epub 2009 Jul 24.

10.

Wnt antagonist gene polymorphisms and renal cancer.

Hirata H, Hinoda Y, Nakajima K, Kikuno N, Yamamura S, Kawakami K, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R.

Cancer. 2009 Oct 1;115(19):4488-503. doi: 10.1002/cncr.24491.

11.

The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer.

Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, Ishii N, Dahiya R.

J Urol. 2009 Aug;182(2):721-7. doi: 10.1016/j.juro.2009.03.081. Epub 2009 Jun 18.

PMID:
19539330
12.

Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.

Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, Tabatabai ZL, Igawa M, Dahiya R.

J Urol. 2009 Apr;181(4):1907-12. doi: 10.1016/j.juro.2008.11.093. Epub 2009 Feb 23.

PMID:
19237173
13.

Nerve growth factor combined with vascular endothelial growth factor enhances regeneration of bladder acellular matrix graft in spinal cord injury-induced neurogenic rat bladder.

Kikuno N, Kawamoto K, Hirata H, Vejdani K, Kawakami K, Fandel T, Nunes L, Urakami S, Shiina H, Igawa M, Tanagho E, Dahiya R.

BJU Int. 2009 May;103(10):1424-8. doi: 10.1111/j.1464-410X.2008.08129.x. Epub 2008 Oct 14.

14.

Genistein mediated histone acetylation and demethylation activates tumor suppressor genes in prostate cancer cells.

Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Majid S, Igawa M, Dahiya R.

Int J Cancer. 2008 Aug 1;123(3):552-60. doi: 10.1002/ijc.23590. Retraction in: Int J Cancer. 2017 Oct 1;141(7):1492.

15.

Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification.

Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, Place RF, Pookot D, Dahiya R.

Cancer Res. 2008 Apr 15;68(8):2736-44. doi: 10.1158/0008-5472.CAN-07-2290.

16.

DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.

Kawamoto K, Hirata H, Kikuno N, Tanaka Y, Nakagawa M, Dahiya R.

Int J Cancer. 2008 Aug 1;123(3):535-42. doi: 10.1002/ijc.23514.

17.

Mismatch repair gene MSH3 polymorphism is associated with the risk of sporadic prostate cancer.

Hirata H, Hinoda Y, Kawamoto K, Kikuno N, Suehiro Y, Okayama N, Tanaka Y, Dahiya R.

J Urol. 2008 May;179(5):2020-4. doi: 10.1016/j.juro.2008.01.009. Epub 2008 Mar 20.

18.

COMT polymorphisms affecting protein expression are risk factors for endometrial cancer.

Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Rabban JT, Chen LM, Dahiya R.

Mol Carcinog. 2008 Oct;47(10):768-74. doi: 10.1002/mc.20432.

PMID:
18324659
19.

CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility.

Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Rabban JT, Chen LM, Dahiya R.

Cancer. 2008 May 1;112(9):1964-73. doi: 10.1002/cncr.23392.

20.

CXCL12 G801A polymorphism is a risk factor for sporadic prostate cancer susceptibility.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Dahiya AV, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Sep 1;13(17):5056-62.

21.

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.

Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R.

Clin Cancer Res. 2007 Jul 15;13(14):4123-9.

22.

Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.

Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, Tanaka Y, Place RF, Pookot D, Majid S, Igawa M, Dahiya R.

Oncogene. 2007 Dec 6;26(55):7647-55. Epub 2007 Jun 11.

PMID:
17563745
23.

Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer.

Kawamoto K, Okino ST, Place RF, Urakami S, Hirata H, Kikuno N, Kawakami T, Tanaka Y, Pookot D, Chen Z, Majid S, Enokida H, Nakagawa M, Dahiya R.

Clin Cancer Res. 2007 May 1;13(9):2541-8.

24.

Functional improvement in spinal cord injury-induced neurogenic bladder by bladder augmentation using bladder acellular matrix graft in the rat.

Urakami S, Shiina H, Enokida H, Kawamoto K, Kikuno N, Fandel T, Vejdani K, Nunes L, Igawa M, Tanagho EA, Dahiya R.

World J Urol. 2007 Apr;25(2):207-13. Epub 2007 Jan 13.

PMID:
17221271
25.

Polymorphisms of catechol-O-methyltransferase in men with renal cell cancer.

Tanaka Y, Hirata H, Chen Z, Kikuno N, Kawamoto K, Majid S, Tokizane T, Urakami S, Shiina H, Nakajima K, Dhir R, Dahiya R.

Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):92-7.

26.

Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.

Kikuno N, Urakami S, Nakamura S, Hiraoka T, Hyuga T, Arichi N, Wake K, Sumura M, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M.

Eur Urol. 2007 May;51(5):1252-8. Epub 2006 Dec 26.

PMID:
17208356
27.
28.

Polymorphisms of DNA repair genes are risk factors for prostate cancer.

Hirata H, Hinoda Y, Tanaka Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, Majid S, Vejdani K, Dahiya R.

Eur J Cancer. 2007 Jan;43(2):231-7. Epub 2006 Dec 29.

PMID:
17196815
29.

Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.

Urakami S, Shiina H, Enokida H, Hirata H, Kawamoto K, Kawakami T, Kikuno N, Tanaka Y, Majid S, Nakagawa M, Igawa M, Dahiya R.

Clin Cancer Res. 2006 Dec 1;12(23):6989-97.

30.

Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.

Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24.

31.

Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection.

Urakami S, Shiina H, Enokida H, Kawakami T, Kawamoto K, Hirata H, Tanaka Y, Kikuno N, Nakagawa M, Igawa M, Dahiya R.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16.

32.

Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.

Urakami S, Shiina H, Enokida H, Kawakami T, Tokizane T, Ogishima T, Tanaka Y, Li LC, Ribeiro-Filho LA, Terashima M, Kikuno N, Adachi H, Yoneda T, Kishi H, Shigeno K, Konety BR, Igawa M, Dahiya R.

Clin Cancer Res. 2006 Jan 15;12(2):383-91.

33.

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.

Urakami S, Yoshino T, Kikuno N, Imai S, Honda S, Yoneda T, Kishi H, Shigeno K, Shiina H, Igawa M.

Urology. 2005 Mar;65(3):543-8.

PMID:
15780373
34.

Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.

Kikuno N, Moriyama-Gonda N, Yoshino T, Yoneda T, Urakami S, Terashima M, Yoshida M, Kishi H, Shigeno K, Shiina H, Igawa M.

Cancer Res. 2004 Oct 15;64(20):7526-32.

35.

Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis.

Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H.

J Urol. 2004 May;171(5):1855-60.

PMID:
15076293
36.

The role of thymidine phosphorylase (TP) mRNA expression in angiogenesis of prostate cancer.

Kikuno N, Yoshino T, Urakami S, Shigeno K, Kishi H, Hata K, Shiina H, Igawa M.

Anticancer Res. 2003 Mar-Apr;23(2B):1305-12.

PMID:
12820387
37.

Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.

Urakami S, Igawa M, Kikuno N, Yoshino T, Kishi H, Shigeno K, Shiina H.

J Urol. 2002 Dec;168(6):2444-50.

PMID:
12441936
38.
39.

Recurrent transitional cell carcinoma in a child with the Costello syndrome.

Urakami S, Igawa M, Shiina H, Shigeno K, Kikuno N, Yoshino T.

J Urol. 2002 Sep;168(3):1133-4. No abstract available.

PMID:
12187253
40.

Urachal carcinoma associated with increased carbohydrate antigen 19-9 and carcinoembryonic antigen.

Kikuno N, Urakami S, Shigeno K, Shiina H, Igawa M.

J Urol. 2001 Aug;166(2):604. No abstract available.

PMID:
11458079

Supplemental Content

Loading ...
Support Center